In 2023, the treatment success rate for patients treated for multidrug-resistant tuberculosis (MDR-TB) in China was recorded at 57%. The forecast from 2024 to 2028 indicates a gradual upward trend, with an increase to 58% in 2024 and 2025, 59% in 2026, and reaching 60% in 2027 and 2028. The year-on-year variations suggest a steady improvement, growing 1% annually from 2025 onwards. The compound annual growth rate (CAGR) from 2024 to 2028 is approximately 1.68%, reflecting a cautious yet positive progression.
Future trends to watch will include the potential impact of new treatment methodologies, innovations in healthcare delivery, and policy interventions aimed at improving MDR-TB treatment outcomes in China. Monitoring these factors could provide insights into accelerating progress beyond the current forecast trajectory.
